South Africa Atopic Dermatitis Drugs Market Size & Outlook

The atopic dermatitis drugs market in South Africa is expected to reach a projected revenue of US$ 109.3 million by 2030. A compound annual growth rate of 9.7% is expected of South Africa atopic dermatitis drugs market from 2025 to 2030.
Revenue, 2024 (US$M)
$62.1
Forecast, 2030 (US$M)
$109.3
CAGR, 2025 - 2030
9.7%
Report Coverage
South Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

South Africa atopic dermatitis drugs market, 2018-2030 (US$M)

South Africa atopic dermatitis drugs market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

South Africa atopic dermatitis drugs market highlights

  • The South Africa atopic dermatitis drugs market generated a revenue of USD 62.1 million in 2024 and is expected to reach USD 109.3 million by 2030.
  • The South Africa market is expected to grow at a CAGR of 9.7% from 2025 to 2030.
  • In terms of segment, biologics was the largest revenue generating drug class in 2024.
  • PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.

Atopic dermatitis drugs market data book summary

Market revenue in 2024USD 62.1 million
Market revenue in 2030USD 109.3 million
Growth rate9.7% (CAGR from 2025 to 2030)
Largest segmentBiologics
Fastest growing segmentPDE4 Inhibitors
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCorticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics
Key market players worldwidePfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma

Other key industry trends

  • In terms of revenue, South Africa accounted for 0.4% of the global atopic dermatitis drugs market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, Saudi Arabia atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2030.
  • South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 109.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Atopic Dermatitis Drugs Market Companies

Name Profile # Employees HQ Website
LEO Pharma View profile 1001-5000 Parsippany, New Jersey, United States, North America http://www.leo-pharma.us/
Incyte Corp View profile 2524 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 https://www.incyte.com
Regeneron Pharmaceuticals Inc View profile 13450 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 https://www.regeneron.com
Eli Lilly and Co View profile 43000 Lilly Corporate Center, Indianapolis, IN, United States, 46285 https://www.lilly.com
Galderma Group AG Registered Shares View profile - Zählerweg 10, Zug, Switzerland, 6300 https://www.galderma.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com
Otsuka Holdings Co Ltd View profile 39548 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan, 101-0048 http://www.otsuka.com/jp
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

South Africa atopic dermatitis drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.


Biologics was the largest segment with a revenue share of 45.25% in 2024. Horizon Databook has segmented the South Africa atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.


The Government of South Africa has made improvements in the country’s basic healthcare reforms by providing free primary healthcare & diagnostic services to children & pregnant ladies. The South African government has also collaborated with the United Nations Organization to improve healthcare measures, thereby decreasing emergency case rates and increasing life expectancy.

Over the past decade, the prevalence of atopic dermatitis in the country has increased. For instance, the prevalence in children is as high as 23.3%. As per Springer Journal, in 2019, factors such as lack of sanitation and hygiene have contributed significantly to the rise in prevalence of atopic dermatitis in South Africa.

Reasons to subscribe to South Africa atopic dermatitis drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of South Africa atopic dermatitis drugs market databook

  • Our clientele includes a mix of atopic dermatitis drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the South Africa atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into South Africa atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

South Africa atopic dermatitis drugs market size, by drug class, 2018-2030 (US$M)

South Africa Atopic Dermatitis Drugs Market Outlook Share, 2024 & 2030 (US$M)

South Africa atopic dermatitis drugs market size, by drug class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online